Multiple Myeloma Posts on Medivizor
Navigation Menu

Multiple Myeloma Posts on Medivizor

Adding daratumumab to pomalidomide and dexamethasone therapy for treatment of relapsed/refractory multiple myeloma.

Adding daratumumab to pomalidomide and dexamethasone therapy for treatment of relapsed/refractory multiple myeloma.

Posted by on Jul 17, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding daratumumab (Darzalex) to pomalidomide (Pomalyst) and dexamethasone (Decadron) therapy for patients with previously treated relapsed or refractory (r/r) multiple myeloma (MM). The data showed that adding daratumumab to pomalidomide and dexamethasone regimen reduced the risk of...

Read More

Is Ixazomib, thalidomide and dexamethasone effective in treating relapsed and/or refractory multiple myeloma?

Is Ixazomib, thalidomide and dexamethasone effective in treating relapsed and/or refractory multiple myeloma?

Posted by on Jul 11, 2021 in Multiple Myeloma | 0 comments

In a nutshell This article looked at the effectiveness and safety of continuous ixazomib (Ninlaro), thalidomide (Thalomid), and dexamethasone (Decadron) (ITd) in the treatment of relapsed and/or refractory (RR) multiple myeloma (MM). The authors found that this regimen was well tolerated and showed promising effectiveness in the treatment of...

Read More

Real-life experience with autologous stem cell transplantation in patients with multiple myeloma.

Real-life experience with autologous stem cell transplantation in patients with multiple myeloma.

Posted by on Jun 13, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study reported the use of autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). The data showed improved outcomes in patients that received ASCT compared to those who did not. Some background MM is a cancer of plasma cells (myeloma cells). One therapeutic option is high-dose melphalan...

Read More

Reviewing treatment options for bone disease in patients with multiple myeloma

Reviewing treatment options for bone disease in patients with multiple myeloma

Posted by on Jun 6, 2021 in Multiple Myeloma | 0 comments

In a nutshell This article reviewed different treatment options for multiple myeloma (MM)-related bone disease.  Some background MM is a type of cancer of the bone marrow that can lead to abnormal immune cells. Up to 80% of newly diagnosed patients develop bone disease. These patients have a high risk of bone problems, such as fractures and...

Read More

Comparing carfilzomib to bortezomid combined with cyclophosphamide and dexamethasone in patients with previously treated multiple myeloma

Comparing carfilzomib to bortezomid combined with cyclophosphamide and dexamethasone in patients with previously treated multiple myeloma

Posted by on Jun 5, 2021 in Multiple Myeloma | 0 comments

In a nutshell This trial was carried out to compare bortezomib (Velcade; V) and carfilzomib (Kyprolis; K) in combination with Cd (cyclophosphamide and dexamethasone) as second line treatment in patients with relapsed multiple myeloma (MM). The authors found the KCd is as effective as VCd and K can also be used as a maintenance treatment in these...

Read More

Evaluating treatments and long-term outcomes for older or unfit patients with multiple myeloma

Evaluating treatments and long-term outcomes for older or unfit patients with multiple myeloma

Posted by on May 30, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the treatments and long-term outcomes of older and unfit patients with newly diagnosed multiple myeloma (MM). The authors concluded that first-line therapies vary widely among patients, and high-risk patients may receive less effective treatment. Some background MM is a type of cancer of the bone marrow that can...

Read More

Evaluating the effectiveness and safety of different regimens of containing pegylated liposomal doxorubicin in patients with newly diagnosed multiple myeloma.

Evaluating the effectiveness and safety of different regimens of containing pegylated liposomal doxorubicin in patients with newly diagnosed multiple myeloma.

Posted by on May 22, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the effectiveness and safety of different regimens containing pegylated liposomal doxorubicin (PLD; Doxil) for patients with newly diagnosed multiple myeloma (NDMM). The data showed that the different PLD treatment regimens had promising effectiveness with manageable side effects. Some background Multiple...

Read More

Adding isatuximab to pomalidomide-dexamethasone therapy for relapsed/refractory multiple myeloma.

Adding isatuximab to pomalidomide-dexamethasone therapy for relapsed/refractory multiple myeloma.

Posted by on May 16, 2021 in Multiple Myeloma | 0 comments

In a nutshell The aim of this study was to evaluate the addition of isatuximab (Sarclisa) to pomalidomide (Pomalyst) and dexamethasone (Decadron) therapy for patients with relapsed/refractory (r/r) multiple myeloma (MM). The study found that patients who were given isatuximab had a better outcome. Some background MM is a type of blood cancer...

Read More

Adding selinexor to Vd regimen for older or more frail patients with multiple myeloma.

Adding selinexor to Vd regimen for older or more frail patients with multiple myeloma.

Posted by on May 14, 2021 in Multiple Myeloma | 0 comments

In a nutshell The aim of this study was to evaluate the safety and effectiveness of adding selinexor (X; Xpovio) to the Vd (bortezomib and dexamethasone) regimen in older, frail patients with multiple myeloma (MM). The study found that the addition of selinexor to Vd (XVd) was safe and gave older, more frail patients a better...

Read More

Is daratumumab plus RVd a good treatment for patients with newly diagnosed multiple myeloma in the long-term?

Is daratumumab plus RVd a good treatment for patients with newly diagnosed multiple myeloma in the long-term?

Posted by on May 6, 2021 in Multiple Myeloma | 0 comments

In a nutshell The aim of this study was to evaluate the long-term safety and effectiveness of adding daratumumab (Darzalex) to RVd (lenalidomide/bortezomib/dexamethasone) therapy, followed by D-R (daratumumab/lenalidomide) maintenance for patients with newly diagnosed multiple myeloma (MM). The study found that this treatment was well tolerated...

Read More

Evaluating the combination of vorinostat with bortezomib and dexamethasone in relapsed myeloma.

Evaluating the combination of vorinostat with bortezomib and dexamethasone in relapsed myeloma.

Posted by on Apr 25, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the effectiveness and safety of combining vorinostat (Zolinza) with bortezomib (Velcade) and dexamethasone (Decadron) in patients with relapsed multiple myeloma (MM). The data showed that the treatment combination had promising effectiveness but with side effects. Some background Multiple...

Read More